Skip to Content
Merck

Targeted deletion of Interleukin-3 results in asthma exacerbations.

iScience (2022-06-17)
Julia Kölle, Theodor Zimmermann, Alexander Kiefer, Ralf J Rieker, Paraskevi Xepapadaki, Sebastian Zundler, Nikolaos G Papadopoulos, Susetta Finotto
ABSTRACT

The cytokine interleukin-3 (IL-3) acts on early hematopoietic precursor cells. In humans, Treg cells secrete IL-3 and repress inflammatory cells except for basophils. The present study aims to elucidate the contribution of IL-3 in the development and the course of allergic asthma. We therefore analyzed the secretion of IL-3 in PBMCs and total blood cells in two cohorts of pre-school children with and without asthma. In a murine model of allergic asthma, we analyzed the phenotype of IL-3-/- mice compared to wild-type mice. PBMCs from asthmatic children showed increased IL-3 secretion, which directly correlated with improved lung function. IL-3-/- asthmatic mice showed increased asthmatic traits. Moreover, IL-3-deficient mice had a defect in T regulatory cells in the lung. In conclusion, IL-3 downregulation was found associated with more severe allergic asthma in pre-school children. Consistently, targeting IL-3 resulted in an induced pathophysiological response in a murine model of allergic asthma.

MATERIALS
Product Number
Brand
Product Description

Roche
Phytohemagglutinin-M (PHA-M), from Phaseolus vulgaris